Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE1 first-line treatment optimization platform in metastatic renal cell carcinoma
NL-OMON58868Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in renal cell carcinoma (RCC) (2 arms), sponsored by Gustave Roussy. Primary endpoints: Overall survival and Progression-free survival according to RECIST 1.1. Started Apr 2025; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON58868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58868.